The quantity field is empty. Please enter a quantity of 1 or more to add items to your cart.
Description
Overview
A potent, nonselective, and noncompetitive antagonist of nAChRs (IC50 = 640 nM, 2.5 µM, 3.6 µM and 6.9 µM for α3β4, α4β2, α3β2 and α7 subtype nAChRs, respectively). Biologically viable admitted orally or systematically. Widely used in investigating the roles of central nAChRs in the brain functions (learning and memory, decision making, cognition) and disorders (addiction, Autisms, Tourette's syndrome, Schizophrenia and various cognitive and mood disorders).
Harris, C., et al. 2013. Psychopharmacol.225, 291. Lima, H., et al. 2013. Learning & Memory20, 120. Arnold, E., et al. 2012. J. Child Adolesc. Psychopharmacol.22, 198.
Bacher, I., et al. 2009. Expert Opin. Pharmacother.10, 2709. Lippiello, M., et al. 2008. CNS Neurosci. Ther.14, 266.br>J. M. Young et al. 2001. Clin. Ther.23, 532.
Toxic if swallowed. Irritating to eyes, respiratory system and skin.
S Phrase
S: 22-26-28.1-36/37/39-46-63
Do not breathe dust. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. After contact with skin, wash immediately with plenty of water. Wear suitable protective clothing, gloves and eye/face protection. If swallowed, seek medical advice immediately and show this container or label. In case of accident by inhalation: remove casualty to fresh air and keep at rest.
Product Usage Statements
Storage and Shipping Information
Ship Code
Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
Toxicity
Toxic
Hazardous Materials Attention:
Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.
Storage
+2°C to +8°C
Protect from Light
Protect from light
Do not freeze
Ok to freeze
Special Instructions
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Transport Information
Supplemental Information
Specifications
Documentation
Mecamylamine Hydrochloride - CAS 826-39-1 - Calbiochem SDS
Mecamylamine Hydrochloride - CAS 826-39-1 - Calbiochem Certificates of Analysis
Title
Lot Number
505207
References
Reference overview
Harris, C., et al. 2013. Psychopharmacol.225, 291. Lima, H., et al. 2013. Learning & Memory20, 120. Arnold, E., et al. 2012. J. Child Adolesc. Psychopharmacol.22, 198.
Bacher, I., et al. 2009. Expert Opin. Pharmacother.10, 2709. Lippiello, M., et al. 2008. CNS Neurosci. Ther.14, 266.br>J. M. Young et al. 2001. Clin. Ther.23, 532.
Data Sheet
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.
A potent, nonselective, and noncompetitive antagonist of nAChRs (IC50 = 640 nM, 2.5 µM, 3.6 µM and 6.9 µM for α3β4, α4β2, α3β2 and α7 subtype nAChRs, respectively). Biologically viable admitted orally or systematically. Widely used in investigating the roles of central nAChRs in the brain functions (learning and memory, decision making, cognition) and disorders (addiction, Autisms, Tourette's syndrome, Schizophrenia and various cognitive and mood disorders).
Form
Off-white solid
CAS number
826-39-1
Chemical formula
C₁₁H₂₁N•HCl
Structure formula
Purity
≥98% by TLC
Solubility
H₂O (100 mM)
Storage
Protect from light
+2°C to +8°C
Do Not Freeze
Ok to freeze
Special Instructions
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity
Toxic
References
Harris, C., et al. 2013. Psychopharmacol.225, 291. Lima, H., et al. 2013. Learning & Memory20, 120. Arnold, E., et al. 2012. J. Child Adolesc. Psychopharmacol.22, 198.
Bacher, I., et al. 2009. Expert Opin. Pharmacother.10, 2709. Lippiello, M., et al. 2008. CNS Neurosci. Ther.14, 266.br>J. M. Young et al. 2001. Clin. Ther.23, 532.
